2024-11-28 - Analysis Report
## Teladoc Health Inc (TDOC) Stock Report

This report analyzes Teladoc Health Inc (TDOC), a telehealth company providing virtual care services, based on the provided data.

**1. Performance Comparison & Divergence:**

Teladoc's cumulative return of -60.49% significantly underperforms the S&P 500 (VOO) with a cumulative return of 127.43%.  The difference is a staggering -187.9%, placing it at the 8th percentile (0.8 on a 0-1 scale) of its historical performance relative to the S&P 500.  The provided CAGR data shows periods of strong growth followed by significant declines, highlighting the volatility of the stock.  The high negative Alpha values in recent years (-3.8, -3.9) indicate substantial underperformance compared to the benchmark.  The Beta fluctuates, suggesting sensitivity to market movements, but recently it has been quite low (around 2.0), indicating slightly lower than average volatility compared to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $11.43 (Last Market: $11.44)
* **5-Day Moving Average:** $11.17
* **20-Day Moving Average:** $9.72
* **60-Day Moving Average:** $9.05

The price is above all three moving averages, suggesting a short-term bullish trend.  However, the relatively small difference between the closing price and the 5-day moving average hints at some consolidation or minor upward momentum.


**3. Technical Indicators & Relative Divergence:**

* **RSI (65.89):**  Approaching overbought territory, suggesting potential for a short-term pullback.
* **PPO (2.43):** Positive, indicating upward momentum.
* **20-Day Relative Strength Divergence (0.6 +):** Shows a short-term upward trend relative to the S&P 500.
* **Expected Return (0.0%):**  The expected return over two years is projected to be zero compared to the S&P 500. This aligns with the substantial underperformance noted previously.  This figure warrants further investigation as a zero return is unlikely if held for two years and may indicate that the model considers further negative growth as probable.

The closing price of $11.44 is not significantly higher than previous levels. There's no evidence of a rapid surge or sharp decline given the context.

**4. Recent Financial Performance:**

The company's recent financial performance reveals consistent negative EPS. Revenue is relatively stable around $0.64-$0.66B, but consistent net losses are concerning.  The provided October 31st, 2024 EPS figure needs to be compared against analyst expectations to determine if it's a positive or negative surprise.  Further analysis is needed, including an examination of the company's cash flow and debt levels, to evaluate the sustainability of their operations.


**5. Quarterly Financial Data:**

* **Revenue and Profitability:** Revenue is stable, but profit margins, although high, remain unchanged.
* **Capital and Profitability:**  ROE is consistently negative, indicating that the company is not generating returns on its equity.  The significant fluctuation in equity from Q1 to Q2 2024 requires further investigation to understand the underlying reasons.

The financial data clearly demonstrates ongoing profitability challenges and a concerning trend.


**6. News and Recent Issues:**

*(This section requires access to real-time news sources such as Shacknews and Finbold to provide information on recent earnings announcements, analyst opinions, market outlook, and performance highlights within the last two days.  Please provide these news articles for a complete analysis.)*


**7. Overall Analysis:**

Teladoc's stock performance has been significantly underperforming the S&P 500 over the long term. While recent price action shows some short-term positive momentum, the negative EPS, low ROE, and overall negative financial performance raise serious concerns. Technical indicators suggest a potential short-term pullback, and the low expected return versus the S&P 500 reinforces the bleak outlook for long-term returns. Further investigation into recent news, analyst forecasts (particularly regarding the October 2024 EPS), and the cause of the significant equity fluctuation are crucial before making any investment decisions.  The current situation signals high risk and low reward, especially for long-term investors.


**8. Recommendations:**

Based on the available data, a cautious approach is advised. Thoroughly review recent news and analyst reports focusing on the October 2024 earnings and the reasons behind the fluctuations in equity. Further due diligence, including analyzing cash flow, debt levels, and the overall competitive landscape of the telehealth industry, is essential before considering any investment.  The current financial performance and market outlook suggest a high level of risk associated with this stock.
